STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME

Reuters · 01/07 12:00

Please log in to view news